Effect of Helicobacter pylori Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer

Young-Il Kim; Soo-Jeong Cho; Jong Yeul Lee; Chan Gyoo Kim; Myeong-Cherl Kook; Keun Won Ryu; Young-Woo Kim; Il Ju Choi

doi:10.4143/crt.2015.264

Articles

Page Path: HOME > Cancer Res Treat > Volume 48(3); 2016 > Article

Original Article Effect of Helicobacter pylori Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer: Young-Il Kim, MD, Soo-Jeong Cho, MD, PhD, Jong Yeul Lee, MD, Chan Gyoo Kim, MD, PhD, Myeong-Cherl Kook, MD, PhD, Keun Won Ryu, MD, PhD, Young-Woo Kim, MD, PhD, Il Ju Choi, MD, PhD; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2016;48(3):1020-1029.
DOI: https://doi.org/10.4143/crt.2015.264
Published online: November 17, 2015

Center for Gastric Cancer, National Cancer Center, Korea

Correspondence: Il Ju Choi, MD, PhD Center for Gastric Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: 82-31-920-1629 Fax: 82-31-920-0069 E-mail: cij1224@hanmail.net

• Received: July 19, 2015 • Accepted: October 27, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

13,631 Views
208 Download
22 Web of Science
23 Crossref
22 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Negative Helicobacter pylori status has been identified as a poor prognostic factor for survival in gastric cancer (GC) patients who underwent surgery. The aim of this study was to examine the effect of H. pylori eradication on long-term outcomes after distal gastrectomy for GC.
Materials and Methods
We analyzed the survival of 169 distal GC patients enrolled in a prospective randomized trial evaluating histologic changes of gastric mucosa after H. pylori eradication in the remnant stomach. The outcomes measured were overall survival (OS) and GC recurrence rates.
Results
The median follow-up duration was 9.4 years. In the modified intention-to-treat analysis including patients who underwent H. pylori treatment (n=87) or placebo (n=82), 5-year OS rates were 98.9% in the treatment group and 91.5% in the placebo group, and Kaplan-Meier analysis showed no significant difference in OS (p=0.957) between groups. In multivariate analysis, no difference in overall mortality was observed between groups (adjusted hazard ratio [aHR] for H. pylori treatment, 0.75; p=0.495) or H. pylori-eradicated status (aHR for positive H. pylori status, 1.16; p=0.715), while old age, male sex, and advanced stage ≥ IIIa were independent risk factors. Six patients in the treatment group (6.9%) and seven patients in the placebo group (8.5%) had GC recurrences, and GC recurrence rates were not different according to H. pylori treatment (5-year GC recurrence rates, 4.6% in the treatment group vs. 8.5% in the placebo group; p=0.652).
Conclusion
H. pylori eradication for GC patients who underwent distal gastrectomy did not compromise long-term survival after surgery.
Key words: Helicobacter pylori, Stomach Neoplasms, Gastrectomy, Survival

Introduction

Guidelines recommend Helicobacter pylori eradication in patients who undergo distal gastrectomy for treatment of gastric neoplasia [1]. Despite these recommendations, several studies have reported poor long-term outcomes in patients negative for H. pylori infection after gastrectomy [2-4]. In these studies, negative H. pylori status was an independent poor prognostic factor for overall survival (OS) [2,4], gastric cancer-specific survival [3], and relapse-free survival [2]. In addition, gastric cancers in patients without H. pylori infection had poorer clinicopathological features compared with those in patients with H. pylori infection, including larger tumor size, more advanced stage, and more frequent lymph node or distant metastases [3-7].

However, H. pylori eradication or H. pylori–negative status after endoscopic resection for gastric cancer has been associated with a reduced risk for development of metachronous cancers in the remnant stomach [8,9]. In addition, H. pylori eradication leads to improvement of premalignant conditions, such as mucosal atrophy and intestinal metaplasia, in the remnant stomach after gastrectomy [10,11]. Therefore, H. pylori eradication may have beneficial effects, including the potential prevention of metachronous cancers after gastrectomy.

In a previous double-blind randomized controlled study, we reported that H. pylori eradication improved the histological changes of the remnant stomach mucosa, such as atrophy and intestinal metaplasia, after subtotal gastrectomy for gastric cancer [10]. In the current study, we evaluated long-term outcomes, including survival and cancer recurrence, to determine whether H. pylori eradication has a detrimental effect on long-term survival after distal gastrectomy for gastric cancer.

Materials and Methods

1. Study population

We observed patients enrolled in a previous double-blind randomized controlled trial evaluating the effects of H. pylori eradication on mucosal atrophy and intestinal metaplasia in the remnant stomach after distal gastrectomy [10]. Detailed methods were described previously. In brief, newly diagnosed gastric cancer patients aged 18 to 70 years were recruited and screened for eligibility at the National Cancer Center, Korea, between August 2003 and May 2006. Eligibility criteria were as follows: distal gastric adenocarcinoma of clinical stage IA, IB, II, or IIIA according to the 6th edition of the International Union Against Cancer/American Joint Committee on Cancer TNM classification system [12], and positive tests for H. pylori infection. Informed consent was obtained from all participants. The Institutional Review Board of the National Cancer Center, Korea, approved the study protocol (NCCCTS03-063) and the original trial was registered with ClinicalTrials.gov (NCT01002443) [10].

2. H. pylori status evaluation

Both the rapid urea test (RUT) and histology before distal gastrectomy were used for assessment of H. pylori infection. On the initial esophagogastroduodenoscopy (EGD), six biopsy specimens were taken from the lesser curvature of the antrum and the lesser and greater curvatures of the corpus for evaluation of H. pylori status, mucosal atrophy, and intestinal metaplasia. The collected biopsy specimens were immediately fixed in neutral-buffered 10% formalin, embedded in paraffin blocks, and stained with hematoxylin-eosin and Wright-Giemsa for histological evaluation. A single pathologist (M.-C.K.) performed pathological evaluation. One additional biopsy specimen was taken from the greater curvature of the corpus for RUT (Proton Dry, Medical Instruments Corporation, Solothurn, Switzerland). Patients confirmed as H. pylori infection by both a positive RUT and histological evaluation were enrolled in the study.

3. Randomization and surgery

Eligible patients were randomly assigned to the treatment group or the placebo group by computer-generated random number. All investigators and patients were blinded to the randomization results throughout the trial. The treatment group received proton pump inhibitor (PPI)–based standard triple therapy, consisting of rabeprazole 10 mg, clarithromycin 500 mg, and amoxicillin 1,000 mg twice daily for 7 days. The placebo group received the same schedule of rabeprazole 10 mg but received a placebo rather than clarithromycin and amoxicillin. These treatments were administered before distal gastrectomy. Then, all patients underwent an open or laparoscopic distal gastrectomy with D1+ or D2 lymph node dissection [13]. The reconstruction methods were Billroth I (gastroduodenostomy) or II (gastrojejunostomy).

4. Follow-up H. pylori status

Follow-up EGDs with biopsy, RUT, and urea breath test (UBT) were performed at 3 months after distal gastrectomy for assessment of H. pylori status. The biopsy specimens were taken from the lesser and greater curvatures of the corpus, but not the antrum. At the follow-up examination, H. pylori was considered negative if all three tests were negative.

5. Statistical analysis

The calculation of study sample size was described in detail previously [10]. In the current study, outcomes were OS, gastric cancer-specific death, and gastric cancer recurrence. OS and gastric cancer-specific survival were determined from the time of distal gastrectomy to death; OS included deaths from any cause, but gastric cancer-specific death included only death from gastric cancer. Gastric cancer recurrence included metachronous cancer in the remnant stomach, lymph node metastasis, and distant organ metastasis occurring after gastrectomy for distal gastrectomy.

Continuous variables were compared using the Mann-Whitney U test and categorical variables were compared using the chi-square test or Fisher exact test. Follow-up data on deaths and recurrences were obtained until December 2014. The Kaplan-Meier method was used for construction of survival curves, and comparisons were performed using the log-rank test. Comparisons of gastric cancer-specific death and gastric cancer recurrence rates were performed using Gray’s test because of the possible competing risk of death without recurrence. A multivariate Cox proportional hazards model analysis was performed for overall mortality, and a multivariate Fine-Gray regression model analysis was performed for cancer recurrence with competing risks. In model 1, multivariate analyses were performed according to the allocated groups, and in model 2, analyses were performed according to the H. pylori status at 3 months after gastrectomy. Covariates for multivariate analyses were age, sex, and variables having a p-value less than 0.1 in univariate analyses. Analyses were performed using STATA ver. 12.1 (Stata Corp., College Station, TX), except for the Gray’s test, which was analyzed using SAS ver. 9.3 (SAS Inc., Cary, NC). A p-value less than 0.05 was considered statistically significant.

Results

Of the 190 randomized patients, 169 patients who received treatment or placebo were included in the analyses; 87 in the treatment group and 82 in the placebo group. At 3 months after distal gastrectomy, H. pylori infection status was evaluated using UBT, histology, and RUT in 167 patients; 67 patients in the treatment group (81.7%, 67/86 patients) and 15 patients in the placebo group (18.3%, 15/81 patients) were negative for H. pylori infection (Fig. 1). These patients were included in the analyses according to the H. pylori status at 3 months after distal gastrectomy.

Baseline characteristics of the 169 allocated patients and 167 patients who underwent follow-up H. pylori tests at 3 months after gastrectomy are summarized in Table 1. Median age was 57 years (interquartile range [IQR], 48 to 64 years) and the proportion of male patients was 69.2% (117 patients). There were no differences in age, sex, smoking, alcohol drinking, surgical methods, reconstruction methods, pathologic stage, and histology between the treatment and placebo groups. Comparisons according to H. pylori status at 3 months after gastrectomy showed no significant differences in baseline characteristics except for the final cancer stage after surgery; a higher proportion of patients with H. pyloripositive status had stage I cancer compared to those with H. pylori-negative status (80.0% vs. 72.0%, respectively; p=0.033).

1. Comparisons of long-term survival rates after distal gastrectomy

During a median follow-up period of 9.4 years (IQR, 9.0 to 10.2 years; range, 0.7 to 11.3 years), 26 patients died: 14 in the treatment group and 12 in the placebo group. The 5-year OS rates were 98.9% in the treatment group and 91.5% in the placebo group, and results of Kaplan-Meier analysis showed no significant difference between groups (p=0.957 by log-rank test) (Fig. 2A). Overall, 13 patients had gastric cancer recurrence (6 [6.9%] in the treatment group and 7 [8.5%] in the placebo group). Of these, metachronous cancers occurred in 4 patients (3 patients in the treatment group and 1 patient in the placebo group), and the metachronous cancer rates were not different between the treatment group and the placebo group (3.5% vs. 1.5%, p=0.341). One patient died of gastric cancer metastasis at 5 months after total gastrectomy for metachronous cancer, while, the remaining nine patients had lymph node or other organ metastases (3 patients in the treatment group and 6 patients in the placebo group). Of the patients with gastric cancer recurrence, 10 patients died because of gastric cancer recurrence (4 patients in the treatment group and 6 patients in the placebo group). The 5-year incidence rates of gastric cancer recurrence were 4.6% in the treatment group and 8.5% in the placebo group, and Gray’s test showed no statistical significance (p=0.652) (Fig. 2B). No difference in the cumulative incidences of gastric cancer-specific death were observed between the treatment and placebo groups (5-year cumulative incidence rate, 1.1% vs. 6.1%, respectively; p=0.422 by Gray’s test) (Fig. 2C).

At 3 months after gastrectomy, 82 patients had negative H. pylori status and 85 had positive H. pylori status. After gastrectomy, OS did not differ between patients with negative H. pylori status and those with positive H. pylori status (5-year OS rates, 96.3% vs. 94.1%, respectively; p=0.997 by log-rank test) (Fig. 3A). In addition, no statistical differences in gastric cancer recurrence (5-year cumulative incidence rates, 6.1% for negative status vs. 7.1% for positive status; p=0.897 by Gray’s test) (Fig. 3B) and gastric cancer-specific death (5-year cumulative incidence rates, 3.7% for negative status vs. 3.5% for positive status; p=0.792 by Gray’s test) (Fig. 3C) were observed between patients with and without H. pylori at 3 months after distal gastrectomy.

2. Univariate and multivariate analyses for overall mortality and cancer recurrence

In univariate analyses, overall mortality after distal gastrectomy was not affected by H. pylori treatment allocation (crude hazard ratio [cHR] for H. pylori treatment, 1.02; p=0.957) or positive H. pylori status at 3 months after distal gastrectomy (cHR for H. pylori–positive, 1.00; p=0.997). Male sex, Billroth II anastomosis after distal gastrectomy, and stage ≥ IIIa were significant factors associated with overall mortality. In model 1, multivariate analysis according to H. pylori treatment allocation showed that age (adjusted HR [aHR], 1.06; p=0.017), male sex (aHR, 8.38; p=0.005), and advanced stage ≥ IIIa (aHR, 9.18; p < 0.001) were independent risk factors for overall mortality. H. pylori treatment was not a significant factor for overall mortality (aHR for treatment group, 0.75; p=0.495). In model 2, positive H. pylori status at 3 months after gastrectomy did not show significant association with overall mortality (aHR, 1.16; p=0.715), whereas age, male sex, and advanced stage ≥ IIIa were independent risk factors for overall mortality (Table 2).

For cancer recurrence, neither H. pylori treatment (cHR, 0.78; p=0.649) nor positive H. pylori status after gastrectomy (cHR, 1.13; p=0.821) were significant factors in univariate analyses. Multivariate Fine-Gray regression analyses showed that only the advanced stage ≥ IIIa was a significant risk factor in both model 1 and 2. In these analyses, H. pylori treatment (aHR, 0.60; p=0.431) and positive H. pylori status at 3 months after distal gastrectomy (aHR, 1.05; p=0.921) did not affect cancer recurrence (Table 3).

Discussion

In the current long-term follow-up study of a double-blind randomized trial, H. pylori treatment and H. pylori infection status did not affect long-term outcomes after distal gastrectomy, including OS, gastric cancer recurrence, and gastric cancer-specific death. Several studies have reported an association of H. pylori infection status with long-term outcomes after gastrectomy. One prospective [2] and two retrospective studies [3,4] reported that negative H. pylori status is a poor prognostic factor for long-term outcomes after gastrectomy. Meimarakis et al. [2] reported that negative H. pylori status after surgery is an independent risk factor associated with poor OS and recurrence-free survival, and Marrelli et al. [3] reported that negative H. pylori status is a poor prognostic factor for OS. Kang et al. [4] reported an association of negative H. pylori status with poor OS in patients who received adjuvant chemotherapy for locally advanced gastric cancer (stage IB to IV) after gastrectomy. In these studies, the negative H. pylori status group likely included heterogeneous patients who were initially negative for H. pylori infection or those whose H. pylori infection disappeared because of the advances of atrophy or H. pylori treatment. It appears that negative H. pylori status due to any cause may affect long-term survival after gastrectomy. However, our findings suggest that negative H. pylori status resulting from H. pylori treatment does not affect long-term outcomes after distal gastrectomy.

In comparison with H. pylori–positive gastric cancer,H. pylori–negative gastric cancer had the following clinical characteristics: prevalence in younger patients, tumor location in the upper-third portion of the stomach, and more frequent diffuse-type histology [5,7,14]. In addition, H. pylori–negative patients had higher advanced cancer stage [5] or distant metastasis [7], suggesting poor clinical outcomes. In the aforementioned studies that reported poorer long-term survival rates after gastrectomy in H. pylori–negative gastric cancer patients, baseline clinical characteristics were also different between H. pylori–negative and –positive groups. H. pylori–negative patients had a significantly higher proportion of tumors located proximally [2,3], and more of these patients underwent total gastrectomy [2]. H. pylori–negative patients had more advanced tumor stage [3,4] and larger tumor size [4] than H. pylori–positive patients. These findings suggest that H. pylori–negative gastric cancer may be intrinsically associated with poor clinicopathological features. In a recent study, gastric cancers were classified according to molecular subtype [15]. H. pylori infection is also related to some of the molecular changes associated with gastric carcinogenesis, including genetic instability and epigenetic changes in oncogenes or tumor suppressor genes [16]. Different molecular changes are likely in H. pylori–negative gastric cancer compared with H. pylori–positive gastric can cer, which may be associated with poor long-term outcomes.

A possible mechanism for the prognostic role of H. pylori infection after gastrectomy is that H. pylori–induced tumor-specific immune responses may be down-regulated in H. pylori–negative gastric cancer patients, possibly influencing long-term outcomes [2]. However, this mechanism has not been proven in clinical studies, and other factors could affect the outcomes for these patients. In the current study, long-term outcomes were not affected by H. pylori status after gastrectomy; however, age, male sex, and advanced stage were independent risk factors for overall mortality. Advanced stage was also a significant risk factor for cancer recurrence. In addition, Hobsley et al. [17] commented that negative H. pylori status might simply be associated with more advanced tumor progression rather than related to poor prognosis, consistent with our findings.

In our previous study, most H. pylori–negative gastric cancers occurred in patients with past H. pylori infection, and patients who were truly negative for H. pylori infection were rare, occurring at a rate of 2.3% [7]. Compared with true H. pylori–negative gastric cancer patients, gastric cancer patients with past H. pylori infection were older and predominantly male, and had a higher proportion of intestinal-type histology and a lower distant metastasis rate [7]. In the current study, H. pylori–negative patients were those with past H. pylori infection that was eradicated upon treatment with PPI-based standard triple therapy. Clinical characteristics of patients in the H. pylori–negative group may be different from those of true H. pylori–negative gastric cancer patients, and in this instance, long-term outcomes after distal gastrectomy were not affected by H. pylori treatment.

Because of the possible roles of H. pylori infection in carcinogenesis in the remnant stomach mucosa after treatment of gastric cancer [18], guidelines recommend H. pylori eradication to prevent development of new cancers in patients who undergo distal gastrectomy [1]. In patients undergoing gastrectomy, H. pylori infection may induce chronic and active gastritis, and is associated with increased corpus mucosal cell proliferation in the remnant stomach [18-20]. By contrast, H. pylori–negative status is associated with a low risk of mucosal atrophy and intestinal metaplasia in the remnant stomach after gastrectomy [10,11,18,21]. In addition, in early gastric cancer patients undergoing endoscopic resection, a previous randomized controlled study reported that H. pylori treatment reduces the incidence of metachronous cancers [8], and a recent meta-analysis also reported significantly reduced incidences of metachronous gastric neoplasia for H. pylori–eradicated patients [22]. However, in the current study metachronous cancer rates were not different according to H. pylori treatment or according to H. pylori status. This may be because all of the included patients underwent gastric resection of the distal portion of the stomach, which is the common site for synchronous [23] or metachronous cancer [24]. Studies with a proper design and adequate sample size are needed to evaluate the question of whether H. pylori eradication may be a preventive strategy for development of metachronous gastric cancer after distal gastrectomy.

The main strength of this study was that it collected long-term follow-up data from gastric cancer patients who underwent distal gastrectomy in a prospective double-blind randomized controlled trial. Thus, we performed intention-to-treat analysis to determine whether H. pylori treatment affects long-term outcomes after distal gastrectomy in gastric cancer patients.

However, the current study had several limitations. First, the study sample size may not be large enough to evaluate the association between H. pylori infection status and long-term outcomes, because the sample size originally calculated was for the first study, which assessed the histological improvement of the lessor curvature of the corpus after distal gastrectomy [10]. Thus, an additional study including more enrolled patients is needed to provide adequate power. Second, the findings of the current study may not be applicable to areas where the prevalence of H. pylori infection and the incidence of gastric cancer are low. Third, spontaneous clearance of H. pylori infection during follow-up after gastrectomy was reported in the previous study [25]. Therefore, some H. pylori-positive patients in the current study might have spontaneous negative conversion of H. pylori infection after distal gastrectomy, and long-term outcomes might be affected by the spontaneous clearance of H. pylori infection. Finally, clinicopathological characteristics according to the virulence factors of H. pylori strains were not evaluated in the current study.

Conclusion

In conclusion, H. pylori eradication for gastric cancer patients who undergo distal gastrectomy appears to have no effect on long-term survival and cancer recurrence rates after surgery. Thus, H. pylori eradication in gastric cancer patients after distal gastrectomy may be performed without concern for compromising long-term survival.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This work was supported by grant 1310280 from the National Cancer Center, Korea.

Fig. 1.

Study flowchart. EGD, esophagogastroduodenoscopy; H. pylori, Helicobacter pylori; RUT, rapid urease test; UBT, urea breath test.

Fig. 2.

Comparisons of long-term outcomes according to Helicobacter pylori treatment allocation. Overall survival (A), gastric cancer recurrence (B), and gastric cancer specific death curves (C).

Fig. 3.

Comparisons of long-term outcomes according to Helicobacter pylori status at 3 months after distal gastrectomy. Overall survival (A), gastric cancer recurrence (B), and gastric cancer specific death curves (C).

Table 1.

Baseline characteristics

Characteristic	Initial allocation group			Helicobacter pylori status at 3 months after surgery
Characteristic	Placebo (n=82)	Treatment (n=87)	p-value	Negative (n=82)	Positive (n=85)	p-value
Age, median (IQR, yr)	56 (48-64)	58 (48-65)	0.715	57 (46-64)	58 (48-64)	0.743
Sex
Female	21 (25.6)	31 (35.6)	0.158	25 (30.5)	27 (31.8)	0.859
Male	61 (74.4)	56 (64.4)		57 (69.5)	58 (68.2)
Allocation group
Placebo	-	-	-	15 (18.3)	66 (77.7)	< 0.001
Treatment	-	-		67 (81.7)	19 (22.4)
Alcohol drinking
No	35 (42.7)	40 (46.0)	0.667	38 (46.3)	36 (42.4)	0.604
Yes	47 (57.3)	47 (54.0)		44 (53.7)	49 (57.7)
Smoking
No	51 (62.2)	46 (52.9)	0.221	47 (57.3)	49 (57.7)	0.996
Yes	31 (37.8)	41 (47.1)		35 (42.7)	36 (42.4)
Surgical method
Laparoscopic	21 (25.6)	17 (19.5)	0.345	15 (18.3)	22 (25.9)	0.238
Open	61 (74.4)	70 (80.5)		67 (81.7)	63 (74.1)
Reconstruction method
Billroth I (gastroduodenostomy)	63 (76.8)	59 (67.8)	0.191	59 (72.0)	61 (71.8)	0.979
Billroth II (gastrojejunostomy)	19 (23.2)	28 (32.2)		23 (28.1)	24 (28.2)
Histologic type
Differentiated	48 (58.5)	51 (58.6)	0.991	45 (54.9)	54 (63.5)	0.255
Undifferentiated	34 (41.5)	36 (41.4)		37 (45.1)	31 (36.5)
Final cancer stage after surgery
Stage I	66 (80.5)	63 (72.4)	0.257	59 (72.0)	68 (80.0)	0.033
Stage II	10 (12.2)	19 (21.8)		20 (24.4)	9 (10.6)
Stage IIIa or more	6 (7.3)	5 (5.8)		3 (3.7)	8 (9.4)

Values are presented as number (%) unless otherwise indicated. IQR, interquartile range.

Table 2.

Clinical and pathological factors associated with overall mortality

Factor	No.	Univariate analysis^a)		Multivariate analysis^a)
Factor	No.	cHR (95% CI)	p-value	aHR (95% CI)	p-value
*Model 1. Helicobacter pylori* allocation group**
Allocation group
Placebo	82	1.00		1.00
Treatment	87	1.02 (0.47-2.21)	0.957	0.75 (0.32-1.73)	0.495
Age (yr)	169	1.04 (0.99-1.08)	0.119	1.06 (1.01-1.11)	0.017
Sex
Female	52	1.00		1.00
Male	117	6.11 (1.44-25.87)	0.014	8.38 (1.87-37.42)	0.005
Alcohol drinking
No	75	1.00		-
Yes	94	1.23 (0.56-2.69)	0.612	-	-
Smoking
No	97	1.00		-
Yes	72	1.50 (0.69-3.24)	0.305	-	-
Surgical method
Laparoscopic	38	1.00		1.00
Open	131	3.77 (0.89-15.97)	0.071	2.10 (0.47-9.43)	0.335
Reconstruction method
Billroth I (gastroduodenostomy)	122	1.00		1.00
Billroth II (gastrojejunostomy)	47	3.10 (1.42-6.74)	0.004	1.56 (0.62-3.92)	0.344
Histologic type
Differentiated	99	1.00		-
Undifferentiated	70	0.68 (0.30-1.53)	0.348	-	-
Final cancer stage after surgery
Stage I	129	1.00		1.00
Stage II	29	1.63 (0.58-4.60)	0.355	1.80 (0.59-5.46)	0.298
Stage IIIa or more	11	10.45 (4.31-25.38)	< 0.001	9.18 (3.25-25.97)	< 0.001
*Model 2. H. pylori* status at 3 months after surgery**^b)
H. pylori status at 3 months after surgery
Negative	82	1.00		1.00
Positive	85	1.00 (0.46-2.16)	0.997	1.16 (0.52-2.57)	0.715

cHR, crude hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio.

^a) Cox proportional hazards model was used for uni- and multivariate analyses,

^b) Covariates for multivariate analysis in model 2 were age, sex, operation method, reconstruction method, and final cancer stage after surgery.

Table 3.

Clinical and pathological factors associated with gastric cancer recurrence

Factor	No.	Univariate analysis^a)		Multivariate analysis^a)
Factor	No.	cHR (95% CI)	p-value	aHR (95% CI)	p-value
*Model 1. Helicobacter pylori* allocation group**
Allocation group
Placebo	82	1.00		1.00
Treatment	87	0.78 (0.26-2.29)	0.649	0.60 (0.17-2.12)	0.431
Age (yr)	169	1.03 (0.96-1.10)	0.359	1.06 (0.99-1.13)	0.101
Sex
Female	52	1.00		1.00
Male	117	2.50 (0.55-11.35)	0.236	3.38 (0.56-20.54)	0.185
Alcohol drinking
No	75	1.00		-
Yes	94	1.31 (0.44-3.96)	0.629	-	-
Smoking
No	97	1.00		-
Yes	72	2.27 (0.75-6.85)	0.145	-	-
Surgical method
Laparoscopic	38	1.00		-
Open	131	1.63 (0.36-7.33)	0.527	-	-
Reconstruction method
Billroth I (gastroduodenostomy)	122	1.00		1.00
Billroth II (gastrojejunostomy)	47	3.22 (1.10-9.47)	0.033	2.13 (0.48-9.40)	0.319
Histologic type
Differentiated	99	1.00		-
Undifferentiated	70	0.61 (0.19-2.00)	0.416	-	-
Final cancer stage after surgery
Stage I	129	1.00		1.00
Stage II	29	2.30 (0.56-9.44)	0.247	2.50 (0.44-14.03)	0.299
Stage IIIa or more	11	8.76 (2.58-29.70)	< 0.001	7.44 (1.55-35.58)	0.012
*Model 2. H. pylori* status at 3 months after surgery**^b)
H. pylori status at 3 months after surgery
Negative	82	1.00		1.00
Positive	85	1.13 (0.38-3.35)	0.821	1.05 (0.37-2.97)	0.921

cHR, crude hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio.

^a) Fine-Gray regression model was used for uniand multivariate analyses,

^b) Covariates for multivariate analysis in model 2 were age, sex, reconstruction method, and final cancer stage after surgery.

REFERENCES

1. Choi IJ. Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer. Korean J Intern Med. 2013;28:525–37. Article PubMed PMC
2. Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006;7:211–22. Article PubMed
3. Marrelli D, Pedrazzani C, Berardi A, Corso G, Neri A, Garosi L, et al. Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer. 2009;115:2071–80. Article PubMed
4. Kang SY, Han JH, Ahn MS, Lee HW, Jeong SH, Park JS, et al. Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. Int J Cancer. 2012;130:948–58. Article PubMed
5. Yoon H, Kim N, Lee HS, Shin CM, Park YS, Lee DH, et al. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics. Helicobacter. 2011;16:382–8. Article PubMed
6. Qiu HB, Zhang LY, Keshari RP, Wang GQ, Zhou ZW, Xu DZ, et al. Relationship between H. pylori infection and clinicopathological features and prognosis of gastric cancer. BMC Cancer. 2010;10:374.Article PubMed PMC PDF
7. Kwak HW, Choi IJ, Cho SJ, Lee JY, Kim CG, Kook MC, et al. Characteristics of gastric cancer according to Helicobacter pylori infection status. J Gastroenterol Hepatol. 2014;29:1671–7. Article PubMed
8. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–7. Article PubMed
9. Kim YI, Choi IJ, Kook MC, Cho SJ, Lee JY, Kim CG, et al. The association between Helicobacter pylori status and incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer. Helicobacter. 2014;19:194–201. Article PubMed
10. Cho SJ, Choi IJ, Kook MC, Yoon H, Park S, Kim CG, et al. Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. Aliment Pharmacol Ther. 2013;38:477–89. Article PubMed
11. Hwang JJ, Lee DH, Kang KK, Lee AR, Yoon H, Shin CM, et al. Eradication rate and histological changes after Helicobacter pylori eradication treatment in gastric cancer patients following subtotal gastrectomy. World J Gastroenterol. 2015;21:3936–43. Article PubMed PMC
12. Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.
13. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23. Article PubMed PDF
14. Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–9. Article PubMed
15. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9. Article PubMed PMC PDF
16. Hanada K, Graham DY. Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma. Expert Rev Anticancer Ther. 2014;14:947–54. Article PubMed
17. Hobsley M, Tovey FI, Holton J. Helicobacter pylori and gastric cancer: neither friend nor foe. Gastroenterology. 2007;132:2076.Article
18. Lin YS, Chen MJ, Shih SC, Bair MJ, Fang CJ, Wang HY. Management of Helicobacter pylori infection after gastric surgery. World J Gastroenterol. 2014;20:5274–82. Article PubMed PMC
19. Lee Y, Tokunaga A, Tajiri T, Masuda G, Okuda T, Fujita I, et al. Inflammation of the gastric remnant after gastrectomy: mucosal erythema is associated with bile reflux and inflammatory cellular infiltration is associated with Helicobacter pylori infection. J Gastroenterol. 2004;39:520–6. Article PubMed
20. Lynch DA, Mapstone NP, Clarke AM, Jackson P, Dixon MF, Quirke P, et al. Cell proliferation in the gastric corpus in Helicobacter pylori associated gastritis and after gastric resection. Gut. 1995;36:351–3. Article PubMed PMC
21. Sakakibara M, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, et al. Usefulness of Helicobacter pylori eradication for precancerous lesions of the gastric remnant. J Gastroenterol Hepatol. 2014;29 Suppl 4:60–4. Article PubMed
22. Jung DH, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis. PLoS One. 2015;10:e0124725Article PubMed PMC
23. Eom BW, Lee JH, Choi IJ, Kook MC, Nam BH, Ryu KW, et al. Pretreatment risk factors for multiple gastric cancer and missed lesions. J Surg Oncol. 2012;105:813–7. Article PubMed
24. Nasu J, Doi T, Endo H, Nishina T, Hirasaki S, Hyodo I. Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection. Endoscopy. 2005;37:990–3. Article PubMed
25. Bair MJ, Wu MS, Chang WH, Shih SC, Wang TE, Chen CJ, et al. Spontaneous clearance of Helicobacter pylori colonization in patients with partial gastrectomy: correlates with operative procedures and duration after operation. J Formos Med Assoc. 2009;108:13–9. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Relationship between Helicobacter pylori infection and programmed death-ligand 1 in gastric cancer: A meta-analysis
Hong-Chang Yang, Cheng-Feng Fu, Li-Jun Qiao, Gen-He Long, Li-Fen Yang, Biao Yao
World Journal of Clinical Oncology.2025;[Epub] CrossRef
The relationship between the eradication of Helicobacter pylori and the occurrence of stomach cancer: an updated meta-analysis and systemic review
Zhouhan Wu, Yi Tang, Meiwen Tang, Zhoutong Wu, Yonghui Xu
BMC Gastroenterology.2025;[Epub] CrossRef
Changes in Helicobacter pylori Status in Patients Who Underwent Partial Gastrectomy for Gastric Cancer Therapy
Yonghoon Choi
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2025; 25(2): 191. CrossRef
The impact of Helicobacter pylori infection on prognosis in patients with postgastrectomy gastric cancer: A systematic review and meta-analysis
Yu-Wei Cao, Tao Jin, Ze-Hua Chen, Pan-Ping Liang, Yi-Ning Gou, Kun Yang
Surgery.2025; 185: 109512. CrossRef
The influence of H. pylori infection in HER2-positive gastric cancer cell lines: insights from Wnt/β-catenin pathway
Valli De Re, Mariateresa Casarotto, Giulia Brisotto, Stefania Zanussi, Mariangela De Zorzi, Ombretta Repetto, Elena Muraro, Paola Spessotto, Paolo Baldo, Vito Racanelli, Marco Vincenzo Lenti, Marino Venerito, Matteo Fassan, Agostino Steffan, Stefano Reald
Frontiers in Immunology.2025;[Epub] CrossRef
Anti–Helicobacter pylori Treatment in Patients With Gastric Cancer After Radical Gastrectomy
Zhoukai Zhao, Ruopeng Zhang, Guoming Chen, Man Nie, Feiyang Zhang, Xiaojiang Chen, Jun Lin, Zewei Chen, Feizhi Lin, Chengzhi Wei, Ziqi Zheng, Shenghang Ruan, Bowen Huang, Yingbo Chen, Runcong Nie
JAMA Network Open.2024; 7(3): e243812. CrossRef
Helicobacter Pylori and Celiac Disease Antibody Positivity Have a Higher Prevalence in Patients With Distal Gastrectomy: A Cross-Sectional Retrospective Study
Kubilay Issever, Ersin Kuloglu, Demet Sengul, Ali Muhtaroglu, Ahmet Cumhur Dulger
Cureus.2023;[Epub] CrossRef
The influence of partial gastrectomy for gastric cancer on the spontaneous disappearance of Helicobacter pylori: A single‐center prospective study
Senichiro Yanagawa, Nobuaki Fujikuni, Kazuaki Tanabe, Masahiro Nakahara, Toshio Noriyuki
Cancer Reports.2023;[Epub] CrossRef
Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis
Zhifang Jia, Min Zheng, Jing Jiang, Donghui Cao, Yanhua Wu, Yuzheng Zhang, Yingli Fu, Xueyuan Cao
BMC Cancer.2022;[Epub] CrossRef
Effect of gastric cancer screening on long-term survival of gastric cancer patients: results of Korean national cancer screening program
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kyu-Won Jung, Kui Son Choi
Journal of Gastroenterology.2022; 57(7): 464. CrossRef
Current Evidence for a Paradigm Shift in Gastric Cancer Prevention From Endoscopic Screening toHelicobacter pyloriEradication in Korea
Young-Il Kim, Il Ju Choi
Journal of Gastric Cancer.2022; 22(3): 169. CrossRef
Helicobacter Pylori and Gastric Cancer Progression
Marina A. Senchukova
Current Microbiology.2022;[Epub] CrossRef
Identifying Factors Affecting Cancer-related Death in Patients with Adenocarcinoma Gastric Cancer; An Analysis in the Presence of Competing Risks
Malihe Safari, Hossein Mahjub, Habib Esmaeili, Mohamad Abasi, Ghodratollah Roshanaei
International Journal of Cancer Management.2021;[Epub] CrossRef
T stage and venous invasion are crucial prognostic factors for long-term survival of patients with remnant gastric cancer: a cohort study
Kentaro Matsuo, Sang-Woong Lee, Ryo Tanaka, Yoshiro Imai, Kotaro Honda, Kohei Taniguchi, Hideki Tomiyama, Kazuhisa Uchiyama
World Journal of Surgical Oncology.2021;[Epub] CrossRef
Tracking the Virulent Helicobacter pylori Strains Instead of Its Pan-Screening to Prevent Gastric Cancer
Farid Rahimi, Amin Talebi Bezmin Abadi
BioNanoScience.2020; 10(1): 315. CrossRef
Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis
Bo Li, Xiaoqian Lan, Li Wang, Jiani Zhao, Jingli Ding, Hao Ding, Jun Lei, Yiping Wei, Wenxiong Zhang
Microbial Pathogenesis.2020; 142: 104075. CrossRef
Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years
Yonghoon Choi, Nayoung Kim, Chang Yong Yun, Yoon Jin Choi, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Sang-Hoon Ahn, Do Joong Park, Hye Seung Lee, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim
Gastric Cancer.2020; 23(6): 1051. CrossRef
Impact of the timing of Helicobacter pylori eradication on the risk of development of metachronous lesions after treatment of early gastric cancer: a population-based cohort study
Hyun Ju Kim, Yun Jin Kim, Seung In Seo, Woon Geon Shin, Chan Hyuk Park
Gastrointestinal Endoscopy.2020; 92(3): 613. CrossRef
Helicobacter pylori Eradication in Patients Undergoing Gastrectomy: Diagnosis and Therapy
Youn I Choi, Jun-Won Chung
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2020; 20(3): 204. CrossRef
Helicobacter pylori Eradication in Adult Patients with Acute Idiopathic Thrombocytopenic Purpura (ITP)
Minoosh Moghimi, Yousef Mortazavi, Saeed Razavi-Dizaji, Shahrbanoo Keyhanian, Zahra Ghadimi, Sahar Baba Ali, Saeideh Mazloomzadeh, Sattar Jafari, Reza Mansouri, Masoud Asadi-Khiavi
Journal of Advances in Medical and Biomedical Research.2019; 27(124): 1. CrossRef
Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer
Il Ju Choi, Myeong-Cherl Kook, Young-Il Kim, Soo-Jeong Cho, Jong Yeul Lee, Chan Gyoo Kim, Boram Park, Byung-Ho Nam
New England Journal of Medicine.2018; 378(12): 1085. CrossRef
Helicobacter pyloriEradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials
Bum Jun Kim, Hyeong Su Kim, Hyun Joo Jang, Jung Han Kim
Gastroenterology Research and Practice.2018; 2018: 1. CrossRef
Do We Need to Retest of Helicobacter pylori Infection after Gastric Cancer Surgery?
Sang Kil Lee
Gut and Liver.2017; 11(2): 169. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Effect of Helicobacter pylori Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer

Cancer Res Treat. 2016;48(3):1020-1029. Published online November 17, 2015

DOI: https://doi.org/10.4143/crt.2015.264

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Effect of Helicobacter pylori Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer

Fig. 1. Study flowchart. EGD, esophagogastroduodenoscopy; H. pylori, Helicobacter pylori; RUT, rapid urease test; UBT, urea breath test.

Fig. 2. Comparisons of long-term outcomes according to Helicobacter pylori treatment allocation. Overall survival (A), gastric cancer recurrence (B), and gastric cancer specific death curves (C).

Fig. 3. Comparisons of long-term outcomes according to Helicobacter pylori status at 3 months after distal gastrectomy. Overall survival (A), gastric cancer recurrence (B), and gastric cancer specific death curves (C).

Fig. 1.

Fig. 2.

Fig. 3.

Effect of Helicobacter pylori Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer

Characteristic	Initial allocation group			Helicobacter pylori status at 3 months after surgery
Characteristic	Placebo (n=82)	Treatment (n=87)	p-value	Negative (n=82)	Positive (n=85)	p-value
Age, median (IQR, yr)	56 (48-64)	58 (48-65)	0.715	57 (46-64)	58 (48-64)	0.743
Sex
Female	21 (25.6)	31 (35.6)	0.158	25 (30.5)	27 (31.8)	0.859
Male	61 (74.4)	56 (64.4)		57 (69.5)	58 (68.2)
Allocation group
Placebo	-	-	-	15 (18.3)	66 (77.7)	< 0.001
Treatment	-	-		67 (81.7)	19 (22.4)
Alcohol drinking
No	35 (42.7)	40 (46.0)	0.667	38 (46.3)	36 (42.4)	0.604
Yes	47 (57.3)	47 (54.0)		44 (53.7)	49 (57.7)
Smoking
No	51 (62.2)	46 (52.9)	0.221	47 (57.3)	49 (57.7)	0.996
Yes	31 (37.8)	41 (47.1)		35 (42.7)	36 (42.4)
Surgical method
Laparoscopic	21 (25.6)	17 (19.5)	0.345	15 (18.3)	22 (25.9)	0.238
Open	61 (74.4)	70 (80.5)		67 (81.7)	63 (74.1)
Reconstruction method
Billroth I (gastroduodenostomy)	63 (76.8)	59 (67.8)	0.191	59 (72.0)	61 (71.8)	0.979
Billroth II (gastrojejunostomy)	19 (23.2)	28 (32.2)		23 (28.1)	24 (28.2)
Histologic type
Differentiated	48 (58.5)	51 (58.6)	0.991	45 (54.9)	54 (63.5)	0.255
Undifferentiated	34 (41.5)	36 (41.4)		37 (45.1)	31 (36.5)
Final cancer stage after surgery
Stage I	66 (80.5)	63 (72.4)	0.257	59 (72.0)	68 (80.0)	0.033
Stage II	10 (12.2)	19 (21.8)		20 (24.4)	9 (10.6)
Stage IIIa or more	6 (7.3)	5 (5.8)		3 (3.7)	8 (9.4)

Factor	No.	Univariate analysis^a)		Multivariate analysis^a)
Factor	No.	cHR (95% CI)	p-value	aHR (95% CI)	p-value
*Model 1. Helicobacter pylori* allocation group**
Allocation group
Placebo	82	1.00		1.00
Treatment	87	1.02 (0.47-2.21)	0.957	0.75 (0.32-1.73)	0.495
Age (yr)	169	1.04 (0.99-1.08)	0.119	1.06 (1.01-1.11)	0.017
Sex
Female	52	1.00		1.00
Male	117	6.11 (1.44-25.87)	0.014	8.38 (1.87-37.42)	0.005
Alcohol drinking
No	75	1.00		-
Yes	94	1.23 (0.56-2.69)	0.612	-	-
Smoking
No	97	1.00		-
Yes	72	1.50 (0.69-3.24)	0.305	-	-
Surgical method
Laparoscopic	38	1.00		1.00
Open	131	3.77 (0.89-15.97)	0.071	2.10 (0.47-9.43)	0.335
Reconstruction method
Billroth I (gastroduodenostomy)	122	1.00		1.00
Billroth II (gastrojejunostomy)	47	3.10 (1.42-6.74)	0.004	1.56 (0.62-3.92)	0.344
Histologic type
Differentiated	99	1.00		-
Undifferentiated	70	0.68 (0.30-1.53)	0.348	-	-
Final cancer stage after surgery
Stage I	129	1.00		1.00
Stage II	29	1.63 (0.58-4.60)	0.355	1.80 (0.59-5.46)	0.298
Stage IIIa or more	11	10.45 (4.31-25.38)	< 0.001	9.18 (3.25-25.97)	< 0.001
*Model 2. H. pylori* status at 3 months after surgery**^b)
H. pylori status at 3 months after surgery
Negative	82	1.00		1.00
Positive	85	1.00 (0.46-2.16)	0.997	1.16 (0.52-2.57)	0.715

Factor	No.	Univariate analysis^a)		Multivariate analysis^a)
Factor	No.	cHR (95% CI)	p-value	aHR (95% CI)	p-value
*Model 1. Helicobacter pylori* allocation group**
Allocation group
Placebo	82	1.00		1.00
Treatment	87	0.78 (0.26-2.29)	0.649	0.60 (0.17-2.12)	0.431
Age (yr)	169	1.03 (0.96-1.10)	0.359	1.06 (0.99-1.13)	0.101
Sex
Female	52	1.00		1.00
Male	117	2.50 (0.55-11.35)	0.236	3.38 (0.56-20.54)	0.185
Alcohol drinking
No	75	1.00		-
Yes	94	1.31 (0.44-3.96)	0.629	-	-
Smoking
No	97	1.00		-
Yes	72	2.27 (0.75-6.85)	0.145	-	-
Surgical method
Laparoscopic	38	1.00		-
Open	131	1.63 (0.36-7.33)	0.527	-	-
Reconstruction method
Billroth I (gastroduodenostomy)	122	1.00		1.00
Billroth II (gastrojejunostomy)	47	3.22 (1.10-9.47)	0.033	2.13 (0.48-9.40)	0.319
Histologic type
Differentiated	99	1.00		-
Undifferentiated	70	0.61 (0.19-2.00)	0.416	-	-
Final cancer stage after surgery
Stage I	129	1.00		1.00
Stage II	29	2.30 (0.56-9.44)	0.247	2.50 (0.44-14.03)	0.299
Stage IIIa or more	11	8.76 (2.58-29.70)	< 0.001	7.44 (1.55-35.58)	0.012
*Model 2. H. pylori* status at 3 months after surgery**^b)
H. pylori status at 3 months after surgery
Negative	82	1.00		1.00
Positive	85	1.13 (0.38-3.35)	0.821	1.05 (0.37-2.97)	0.921

Table 1. Baseline characteristics

Values are presented as number (%) unless otherwise indicated. IQR, interquartile range.

Table 2. Clinical and pathological factors associated with overall mortality

cHR, crude hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio.

Cox proportional hazards model was used for uni- and multivariate analyses,

Covariates for multivariate analysis in model 2 were age, sex, operation method, reconstruction method, and final cancer stage after surgery.

Table 3. Clinical and pathological factors associated with gastric cancer recurrence

cHR, crude hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio.

Fine-Gray regression model was used for uniand multivariate analyses,

Covariates for multivariate analysis in model 2 were age, sex, reconstruction method, and final cancer stage after surgery.